U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334080) titled 'ECC4703 FE RBA Study in Healthy Adult Participants' on Dec. 30, 2025.

Brief Summary: This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Metabolic Dysfunction-Associated Steatohepatitis

Intervention: DRUG: ECC4703 F0 formulation

A single dose of ECC4703 F0

DRUG: ECC4703 F1 formulation

A single dose of ECC4703 F1

DRUG: ECC4703 F2 formulation

A single dose of ECC4703 F2

DRUG: ECC4703 F3 formulation

A single dose of ECC4703 F3

Recrui...